Having trouble accessing articles? Reset your cache.

Teriflunomide reduces MS relapse rate vs. placebo

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) reported additional data from the Phase III TEMSO trial of teriflunomide

Read the full 154 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE